Psychiatrists – no more $$, thanks – Amid the flak surrounding several prominent psychiatrists (see here and here) and their ties to the drug industry, the American Psychiatric Association has decided to drop all industry-sponsored meals and educational sessions from its annual conferences, the group announced today.
Novo may dodge Takeda‘s fate with new diabetes drug approval by FDA – “Given the Takeda experience, people are more cautious,” said Jack Scannell, a Sanford C. Bernstein & Co. analyst in London. “We’ve gone from a world where people thought liraglutide would sail through the advisory committee to a world where people are aware it’s not a dead certainty.” Scannell expects the drug to “scrape through” the advisory panel meeting, win FDA approval and generate a peak of $1 billion in U.S. revenue by 2013. Its sales potential is limited by gastrointestinal side effects that may lead some patients to opt against it, he said in a telephone interview.
The Pfizer/Ligand osteo drug – Yes in the EU; We’ll see in the United States.
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff